Kurzrock R - Search Results

1

Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.

Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM. Kurzrock R, et al. Clin Cancer Res. 2008 Jan 15;14(2):509-14. doi: 10.1158/1078-0432.CCR-07-1532. Clin Cancer Res. 2008. PMID: 18223226 Clinical Trial.

2

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).

Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO, et al. Estey EH, et al. Among authors: kurzrock r. Blood. 1992 Feb 15;79(4):882-7. Blood. 1992. PMID: 1346577 Free article.

3

Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.

Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Talpaz M, et al. Among authors: kurzrock r. Cancer. 1992 Jan 15;69(2):410-2. doi: 10.1002/1097-0142(19920115)69:2<410::aid-cncr2820690222>3.0.co;2-v. Cancer. 1992. PMID: 1370212

4

Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors.

Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Gutterman JU, Talpaz M. Estrov Z, et al. Among authors: kurzrock r. Blood. 1992 Apr 15;79(8):1938-45. Blood. 1992. PMID: 1373331 Free article.

5

Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.

Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU. Estrov Z, et al. Among authors: kurzrock r. Exp Hematol. 1992 Jun;20(5):558-64. Exp Hematol. 1992. PMID: 1587302

6

The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors.

Estrov Z, Park CH, Reading CL, Estey EH, Talpaz M, Kurzrock R, Deisseroth AB, Gutterman JU. Estrov Z, et al. Among authors: kurzrock r. Exp Hematol. 1992 Aug;20(7):886-90. Exp Hematol. 1992. PMID: 1628706

7

Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.

Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M. Dhingra K, et al. Among authors: kurzrock r. Leukemia. 1992 Aug;6(8):754-60. Leukemia. 1992. PMID: 1640725

8

Fludarabine therapy in macroglobulinemic lymphoma.

Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Kantarjian HM, et al. Among authors: kurzrock r. Blood. 1990 May 15;75(10):1928-31. Blood. 1990. PMID: 1692487 Free article.

9

Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.

Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M. Estrov Z, et al. Among authors: kurzrock r. Blood. 1991 Sep 15;78(6):1476-84. Blood. 1991. PMID: 1715791 Free article.

10

Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.

Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R. Talpaz M, et al. Among authors: kurzrock r. Cancer Res. 1992 Mar 1;52(5):1087-90. Cancer Res. 1992. PMID: 1737366

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,016 results

Search Page

Filters